NASDAQ:LAB Standard BioTools Q3 2026 Earnings Date & Estimates $0.69 +0.02 (+2.85%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.71 +0.02 (+3.57%) As of 10/9/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Standard BioTools is expected to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for November 5, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 3, 2026TimeBefore Market OpensConference Call DateNovember 5, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Standard BioTools in Q3 2026Standard BioTools is expected to post earnings of -$0.02 per share on revenue of $18.80 million. Standard BioTools last reported on August 5, 2026, posting -$0.07 per share and missing the -$0.0128 consensus estimate. Standard BioTools has beaten the consensus EPS estimate in 3 of its last 5 quarters.Consensus EstimatesConsensus EPS-$0.02Expected Revenue$18.80 millionRecent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.07 (Missed by -$0.0573)Last Quarter Revenue$20.10 millionEPS Beat Rate3 of last 5 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ4 2025 Earnings ReportQ2 2024 Earnings Report Standard BioTools Q3 2026 Earnings FAQ When does Standard BioTools report Q3 2026 earnings? Standard BioTools (NASDAQ:LAB) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Standard BioTools' Q3 2026 earnings call? Standard BioTools' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Standard BioTools? Analysts expect Standard BioTools to post earnings of -$0.02 per share for Q3 2026. How much revenue is Standard BioTools expected to report? The consensus revenue estimate for Standard BioTools is $18.80 million for Q3 2026. Standard BioTools Earnings HeadlinesStandard Biotools Agrees To Sell Microfluidics Business To ARCHIMEDOctober 5, 2026 | rttnews.comStandard BioTools to sell microfluidics business to ARCHIMEDOctober 5, 2026 | msn.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 10 at 1:00 AM | Porter & Company (Ad)Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMEDOctober 5, 2026 | globenewswire.comStandard BioTools consensus price target lowered by 12.90% to $1.38October 2, 2026 | msn.comStandard BioTools Inc.: Standard BioTools Provides Update on Sale of Mass Cytometry BusinessOctober 1, 2026 | finanznachrichten.deSee More Standard BioTools Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Standard BioTools? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Standard BioTools and other key companies, straight to your email. Email Address About Standard BioToolsStandard BioTools (NASDAQ:LAB) (NASDAQ:LAB) develops and supplies technologies, instruments and consumables used in biomedical research. Its products are designed to help researchers analyze cells, proteins, genes and other biological systems, supporting applications in immunology, oncology, drug discovery and precision medicine. The company’s offerings include mass cytometry systems, which measure numerous cellular markers simultaneously; imaging mass cytometry platforms for analyzing biomarkers within tissue samples; and microfluidic tools for genomic and single-cell analysis. Following its combination with SomaLogic, Standard BioTools also offers the SomaScan proteomics platform, which enables high-throughput measurement of thousands of proteins in biological samples. Standard BioTools was formerly known as Fluidigm Corporation and adopted its current name in 2022. The company serves academic and government research institutions, pharmaceutical and biotechnology companies, and clinical research organizations internationally. Its corporate headquarters are in South San Francisco, California, and Michael Egholm serves as chief executive officer.View Standard BioTools ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
